Search results for "Hepatitis viru"

showing 10 items of 27 documents

Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity

2016

Background The association between leptin and complement in hepatitis C virus (HCV) infection remains unknown. Methods A prospective study was conducted including 474 (250 genotype 1, 224 genotype 2) consecutive chronic hepatitis C (CHC) patients who had completed an anti-HCV therapy course and undergone pre-therapy and 24-week post-therapy assessments of interferon λ3-rs12979860 and HCV RNA/genotypes, anthropometric measurements, metabolic and liver profiles, and complement component 3 (C3), C4, and leptin levels. Results Of the 474 patients, 395 had a sustained virological response (SVR). Pre-therapy leptin levels did not differ between patients with and without an SVR. Univariate and mul…

0301 basic medicineLeptinRNA virusesMaleSteatosisSustained Virologic ResponsePhysiologyPeptide Hormoneslcsh:MedicineAminotransferasesHepacivirusmedicine.disease_causeGastroenterologyBiochemistryBody Mass IndexCytopathologychemistry.chemical_compoundMathematical and Statistical TechniquesHomeostasisProspective Studieslcsh:SciencePathology and laboratory medicineMultidisciplinaryComplement component 3Hepatitis C virusLeptinAlanine TransaminaseComplement C4Hepatitis CComplement C3Medical microbiologyMiddle AgedLipidsEnzymesmedicine.anatomical_structureCholesterolVirusesPhysical SciencesRNA ViralFemaleViral ClearancePathogensStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyGenotypeHepatitis C virusResearch and Analysis MethodsMicrobiologyAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesTransferasesWhite blood cellInternal medicineVirologymedicineHumansStatistical MethodsAgedMedicine and health sciencesFlavivirusesCholesterolbusiness.industryInterleukinslcsh:ROrganismsViral pathogensBiology and Life SciencesProteinsComplement System ProteinsHepatitis C Chronicmedicine.diseaseHormonesHepatitis virusesMicrobial pathogens030104 developmental biologychemistryAnatomical PathologyImmunologyMultivariate AnalysisEnzymologylcsh:QInterferonsSteatosisbusinessPhysiological ProcessesBody mass indexMathematicsViral Transmission and InfectionPLoS ONE
researchProduct

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients.

2016

The high levels of genetic diversity shown by hepatitis B virus (HBV) are commonly attributed to the low fidelity of its polymerase. However, the rate of spontaneous mutation of human HBV in vivo is currently unknown. Here, based on the evolutionary principle that the population frequency of lethal mutations equals the rate at which they are produced, we have estimated the mutation rate of HBV in vivo by scoring premature stop codons in 621 publicly available, full-length, molecular clone sequences derived from patients. This yielded an estimate of 8.7 × 10-5 spontaneous mutations per nucleotide per cell infection in untreated patients, which should be taken as an upper limit estimate becau…

0301 basic medicineMaleRNA virusesMutation ratelcsh:Medicinemedicine.disease_causeBiochemistryPolymerasesAdefovirFrameshift Mutationlcsh:SciencePathology and laboratory medicineeducation.field_of_studyMultidisciplinaryMicrobial MutationLamivudineMedical microbiologyResistance mutation3. Good healthLamivudineVirusesFemalePathogensSequence AnalysisImmunosuppressive Agentsmedicine.drugResearch ArticleHepatitis B virusSubstitution MutationPopulationOrganophosphonatesBiologyResearch and Analysis MethodsPolymorphism Single NucleotideMicrobiologyFrameshift mutation03 medical and health sciencesHepatitis B ChronicDrug Resistance ViralDNA-binding proteinsmedicineGeneticsHumanseducationMolecular Biology TechniquesSequencing TechniquesMolecular BiologyHepatitis B virusMedicine and health sciencesPoint mutationAdeninelcsh:RViral pathogensOrganismsBiology and Life SciencesProteinsVirologyMolecular biologyHepatitis virusesMicrobial pathogens030104 developmental biologyMutationlcsh:QCloningPLoS ONE
researchProduct

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.

2017

Background and aims A recent meta-analysis revealed that the genotype PNPLA3 rs738409 GG is associated with a higher risk of hepatic steatosis (HS) in Caucasian patients with chronic hepatitis C (CHC). However, controversial results were found regarding Asian populations. Furthermore, previous studies have shown a negative association between interferon lambda 3 (IFNL3) rs12979860 CC and HS in Caucasian CHC patients, but there have been no reports indicating any such association in Asian populations. In this study, then, we investigated the association of PNPLA3 and IFNL3 polymorphisms with HS in Asian CHC patients. Methods We enrolled consecutive CHC patients who underwent liver biopsy pri…

0301 basic medicineRNA virusesMaleSteatosisHeredityPhysiologylcsh:MedicineHepacivirusChronic liver diseasePathology and Laboratory MedicineGastroenterologyBody Mass IndexCytopathologyLiver disease0302 clinical medicineEndocrinologyGenotypeMedicine and Health Scienceslcsh:ScienceMultidisciplinaryAlcohol Consumptionmedicine.diagnostic_testHepatitis C virusFatty liverHepatitis CMedical microbiologyMiddle AgedGenetic MappingPhysiological ParametersLiverLiver biopsyViruses030211 gastroenterology & hepatologyFemalePathogensResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersVariant GenotypesMicrobiologyPolymorphism Single Nucleotide03 medical and health sciencesAsian PeopleInternal medicinemedicineGeneticsDiabetes MellitusHumansGenetic Predisposition to DiseaseAllelesGenetic Association StudiesNutritionAgedFlavivirusesbusiness.industryInterleukinsBody Weightlcsh:ROrganismsViral pathogensBiology and Life SciencesMembrane ProteinsLipaseHepatitis C Chronicmedicine.diseaseFibrosisHepatitis virusesDietMicrobial pathogensFatty Liver030104 developmental biologyAnatomical PathologyGenetic LociMetabolic Disorderslcsh:QInterferonsSteatosisbusinessBody mass indexDevelopmental BiologyPLoS ONE
researchProduct

Characteristics of hepatocellular carcinoma in Italy.

1998

This study aimed to assess the main features of hepatocellular carcinoma at the time of diagnosis in Italy, particularly in relation to the presence or absence of underlying cirrhosis, hepatitis virus marker patterns, age of the subjects and alpha-foetoprotein values.A total of 1148 patients with hepatocellular carcinoma seen at 14 Italian hospitals in the 1-year period from May 1996 to May 1997 were the subjects of this prevalence study. Both newly diagnosed cases (incident cases) and cases diagnosed before May 1996 but still attending the hospitals during the study period (prevalent cases) were included.We found that 71.1% of cases were positive for hepatitis C virus antibodies but negati…

AdultLiver CirrhosisMalemedicine.medical_specialtyHBsAgCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeGastroenterologyAge DistributionInternal medicineHepatitis VirusesmedicinePrevalenceHumansSex DistributionAgedHepatitisAged 80 and overHepatitis B Surface AntigensHepatologybusiness.industryIncidence (epidemiology)Liver NeoplasmsLiver cancer; risk factors; ItalyHepatitis BHepatitis C AntibodiesMiddle Agedmedicine.diseaseLogistic ModelsItalyHepatocellular carcinomaImmunologyRegression AnalysisFemalealpha-FetoproteinsLiver cancerbusinessViral hepatitisJournal of hepatology
researchProduct

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.

2007

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the major risk factors include chronic infections with the hepatitis B (HBV) or C (HCV) virus, and exposure to dietary aflatoxin B(1) (AFB(1)) or alcohol consumption. Multiple genetic and epigenetic changes are involved in the molecular pathogenesis of HCC, for example, somatic mutations in the p53 tumor suppressor gene (TP53) and the activation of the WNT signal transduction pathway. AFB(1) frequently induces G:C to T:A transversions at the third base in codon 249 of TP53 and cooperates with HBV in causing p53 mutations in HCC. The detection of TP53 mutant DNA in plasma is a biomarker of both AFB(1) exposur…

Cancer ResearchAflatoxin B1Carcinoma HepatocellularTumor suppressor geneDNA damageDNA repairBiologymedicine.disease_causeHepatitis VirusesGeneticsmedicineHumansGenetic Predisposition to DiseaseEpigeneticsMolecular BiologyGeneHepatitis ChronicIncidenceLiver Neoplasmsmedicine.diseaseVirologydigestive system diseasesHBxMutagenesisHepatocellular carcinomaMutationCancer researchTumor Suppressor Protein p53CarcinogenesisOncogene
researchProduct

T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease

2012

Generation of antiviral IgM is usually considered as a marker of a short-lived initial antibody response that is replaced by hypermutated and more-efficient IgG. However, once viruses have established a particular niche for their persistence (e.g., within the CNS), the immune system has to specifically mobilize a broad range of antimicrobial effectors to contain the pathogen in the long term. Infection of the CNS with the mouse hepatitis virus (MHV) provides a unique model situation in which the extent of inflammatory CNS disease is determined by the balance between antiviral immune control, viral replication, and immune-mediated damage. We show here that whereas antibody- or B cell-defici…

Central Nervous SystemEnzyme-Linked Immunospot AssayFluorescent Antibody TechniqueVirusMice03 medical and health sciences0302 clinical medicineImmune systemCytidine DeaminaseActivation-induced (cytidine) deaminaseDemyelinating diseasemedicineAnimalsCD40 Antigens030304 developmental biologyMice KnockoutAnalysis of VarianceB-LymphocytesMurine hepatitis virus0303 health sciencesMultidisciplinaryCD40biologyT-Lymphocytes Helper-InducerT helper cellBiological SciencesFlow Cytometrymedicine.diseaseVirology3. Good healthmedicine.anatomical_structureImmunoglobulin MViral replicationImmunologybiology.proteinAntibodyDemyelinating Diseases030215 immunologyProceedings of the National Academy of Sciences
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival

2018

BackgroundCirrhotic cardiomyopathy (CCM) refers to cardiac dysfunction in patients with liver cirrhosis, in the absence of other known cardiac disease.MethodsControl group and patients diagnosed of liver cirrhosis without known cardiac disease or hepatocellular carcinoma were enrolled for this clinical observation study. Patients with diabetes mellitus, hypertension were excluded. Absolute global longitudinal strain, one-point carotid pulse wave velocity (one-point PWV) and various parameters were measured in resting status.ResultsThere were 29 participants in the control group and 80 patients in the liver cirrhosis group. 27.8% of cirrhotic patients presented with normal systolic but abnor…

Liver CirrhosisMaleRNA virusesCirrhosisEtiologySocial SciencesHepacivirus030204 cardiovascular system & hematologyMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesPsychologyCardiac OutputPulse wave velocityPathology and laboratory medicineMultidisciplinaryHepatitis C virusLiver DiseasesQStatisticsRHepatitis CMiddle AgedMedical microbiologyHepatitis CAddictsCirrhosisHepatocellular carcinomaVirusesPhysical SciencesCardiologyMedicineRegression AnalysisFemale030211 gastroenterology & hepatologyPathogensCardiomyopathiesResearch ArticleAdultHepatitis B virusmedicine.medical_specialtyDeath RatesScienceCardiologyDiastoleAddictionGastroenterology and HepatologyPulse Wave AnalysisResearch and Analysis MethodsMicrobiology03 medical and health sciencesPopulation MetricsInternal medicineDiabetes mellitusmedicineHumansAlcoholicsStatistical MethodsAgedHepatitisBiology and life sciencesFlavivirusesPopulation Biologybusiness.industryOrganismsViral pathogensmedicine.diseaseHepatitis virusesCirrhotic cardiomyopathyMicrobial pathogensbusinessMathematicsPLOS ONE
researchProduct

Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".

2022

Dear Editor, Elhence et al.1 assessed the retreatment outcomes of direct‐ acting antivirals (DAAs) therapy failure in a cohort of 40 patients with chronic hepatitis C (HCV) and previous virological failure (VF) to DAAs. The results were remarkable, with an overall sustained virologic response (SVR) of 100% in patients who completed retreatment with sofosbuvir and velpatasvir (with/without ribavirin). We compared these results with our experience in the multicenter HCV‐ Surveillance Cohort Long‐Term Toxicity Antivirals (HCV‐SCOLTA) cohort, an active pharmacovigilance system supported by the CISAI group (Italian Coordinators for the Study of Allergies and HIV Infection). Since 2012, Italian i…

MaleAntiviral agentSustained Virologic ResponseAnti-hepatitis C virus DAA (directly acting antivirals); Antiviral agents; Hepatitis C virus; Hepatitis virus; Virus classification; Antiviral Agents; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Medication Adherence; Middle Aged; Sustained Virologic ResponseHepatitis C virusTreatment outcomeHepacivirusmedicine.disease_causeAntiviral AgentsHepatitis viruMedication AdherenceChronic hepatitisVirologyMedicineHumansIn patientChronicAnti-hepatitis C virus DAA (directly acting antivirals)Virus classificationHepatitis virusVirus classificationHepatitis C virusbusiness.industryAntiviral therapyHepatitis C ChronicMiddle AgedHepatitis CVirologyHepatitis virusInfectious DiseasesItalyFemaleHepatitis C virubusinessDirect actingJournal of medical virology
researchProduct